Checchi, F. and Barrett, M.P. (2008) African sleeping sicknesss - Eflornithine should be the drug of choice for stage 2 disease, but resistance must be monitored. British Medical Journal, 336(7646), pp. 679-680. (doi: 10.1136/bmj.39505.490544.BE)
Full text not currently available from Enlighten.
Publisher's URL: http://dx.doi.org/10.1136/bmj.39505.490544.BE
Abstract
When human African trypanosomiasis (sleeping sickness) killed millions of people during Africa's colonial period 60-100 years ago, interest was similar to that for today's HIV epidemic, but the disease is now largely forgotten. The continuing importance of this disease is highlighted in the accompanying paper by Priotto and colleagues, who report the effectiveness and safety of eflornithine used for its first line treatment.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | No |
Glasgow Author(s) Enlighten ID: | Barrett, Professor Michael |
Authors: | Checchi, F., and Barrett, M.P. |
Subjects: | R Medicine > RA Public aspects of medicine R Medicine > RM Therapeutics. Pharmacology |
College/School: | College of Medical Veterinary and Life Sciences College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
Journal Name: | British Medical Journal |
Journal Abbr.: | BMJ |
Publisher: | BMJ Publishing Group |
ISSN: | 0959-535X |
ISSN (Online): | 1756-1833 |
Copyright Holders: | Copyright © 2008 BMJ Publishing Group |
First Published: | First published in British Medical Journal 336(7646):679-680 |
Publisher Policy: | Reproduced in accordance with the copyright policy of the publisher |
University Staff: Request a correction | Enlighten Editors: Update this record